Skip to main content

Table 1 The patients included in the cytokine study group

From: The increased concentration of macrophage migration inhibitory factor in serum and cerebrospinal fluid of patients with tick-borne encephalitis

 

Sex

Age

Etiology

Presentation

Altered consciousness

Neurologic symptoms

CRP (mg/l)

Leuko-cytosisa

CSF on admission

Pleocytosisa

Neutrophilsa

Lymphocytesa

Proteinb

Albuminb

1

F

32

TBE

M

(−)

(−)

8.2

11,030

174

14

146

70

50

2

F

31

TBE

M

(−)

(−)

 

6720

69

1

66

51

35

3

M

46

TBE

M

(−)

(−)

9.7

13,790

40

4

26

53

37

4

M

21

TBE

M

(−)

(−)

5.6

13,000

228

23

160

81

58

5

M

50

TBE

M

(−)

(−)

12.6

8790

146

39

69

53

36

6

F

70

TBE

M

(−)

(−)

0.8

6140

30

4

23

42

29

7

M

65

TBE

M

(−)

(−)

7.5

8680

46

8

30

85

60

8

F

18

TBE

M

(−)

(−)

2

13,210

266

59

200

50

38

9

M

35

TBE

M

(−)

(−)

1.4

13,440

85

5

75

40

28

10

M

24

TBE

M

(−)

(−)

6.1

7330

76

10

57

61

48

11

M

30

TBE

M

(−)

(−)

22

13,210

122

21

71

64

49

12

M

44

TBE

M

(−)

(−)

5.9

13,960

51

9

37

43

30

13

M

44

TBE

M

(−)

(−)

9.1

11,140

25

10

16

46

35

14

F

49

TBE

ME

(−)

Cerebellar

32.8

10,180

75

22

50

48

40

15

M

18

TBE

ME

(−)

Double vision, unsteady gait

16.1

11,730

103

50

35

59

39

16

F

43

TBE

ME

(−)

Cerebellar

10.8

11,900

56

17

34

45

29

17

M

28

TBE

ME

(−)

Fasciculations, tremor

10.6

13,900

258

21

224

101

73

18

M

28

TBE

ME

(−)

Cerebellar

2.6

9680

176

128

11

48

34

19

M

50

TBE

ME

(−)

Cerebellar

3.1

11,790

134

7

122

65

46

20

M

60

TBE

ME

(−)

Cerebellar

7.4

9150

8

3

 

38

24

21

F

55

TBE

ME

(−)

Cerebellar

6.2

11,270

64

64

0

66

49

22

M

50

TBE

ME

Mild impairment

(−)

17.5

10,120

32

1

24

109

87

23

M

49

TBE

ME

Mild impairment

(−)

10.3

7070

50

6

37

48

37

24

M

27

TBE

ME

Mild impairment

(−)

0.3

10,900

16

  

46

ND

25

M

51

TBE

ME

Mild impairment

Transient hemiparesis

9.5

15,100

22

7

13

29

ND

26

M

55

TBE

ME

Mild impairment

Dysarthria, asymmetric reflexes

 

7020

67

5

46

103

86

27

M

65

TBE

ME

Mild impairment

(−)

0.8

10,085

94

11

61

56

40

28

M

44

TBE

ME

Mild impairment

(−)

15.6

17,060

352

74

243

96

29

29

M

60

TBE

ME

Mild impairment

cerebellar, tremor

16.7

9260

88

22

53

82

46

30

M

38

TBE

ME

Mild impairment

(−)

19.3

11,470

239

38

172

106

85

31

F

45

TBE

ME

Deeply disoriented, agitated

VI cranial nerve paresis

0.5

18,450

1268

1192

38

130

94

32

M

65

TBE

ME

Deeply disoriented, agitated

(−)

1.7

4270

4

  

58

36

33

F

54

TBE

ME

Deeply disoriented, agitated

(−)

17.9

4790

49

22

18

52

36

34

F

45

TBE

ME

Deeply disoriented, agitated

(−)

9.3

11,450

80

10

69

46

36

35

M

57

TBE

MEM

Mild impairment

Paresis of the right arm

16.7

15,100

17

3

 

82

64

36

F

76

TBE

MEM

unconscious

Paresis of the right arm, neck, III cranial nerve bilaterally

4

8860

122

6

116

65

ND

37

M

21

N

M

(−)

(−)

2.8

7890

156

97

50

51

39

38

M

40

N

M

(−)

(−)

19.1

10,460

242

5

198

34

30

39

F

36

N

M

(−)

(−)

4.3

12,340

144

37

101

63

48

40

M

17

N

M

(−)

(−)

1.4

8200

142

18

111

36

27

41

F

26

N

M

(−)

(−)

18

8580

69

0

65

31

20

42

M

25

N

M

(−)

(−)

24.5

9210

102

11

59

47

36

43

F

38

N

ME

(−)

Tremor, double vision

1.7

10,260

311

0

302

165

103

  1. The basic clinical and laboratory data of the patients included in the tick-borne encephalitis study group (TBE) and of the controls with meningitis of different etiology (N)
  2. M meningitis, ME meningoencephalitis, MEM meningoencephalomyelitis, CRP C-reactive protein, ND not done
  3. aIn cells/μl
  4. bIn mg/100 ml